ICH Q5A(R2) · Official Training Modules 0–3

ICH Q5A(R2) Training: Viral Safety Implementation Guide

ICH Q5A(R2) training was developed to help regulators and industry apply the revised viral-safety guideline consistently, especially where the revision introduced new product types, molecular detection technologies, greater use of prior knowledge, and continuous manufacturing. The official Modules 0–3, published in May 2025, are not a replacement for the guideline and do not introduce new requirements. Instead, they use worked examples to illustrate how scientific and risk-based approaches can be justified in practice. The training focuses on three major implementation areas: genetically engineered viral vectors and viral-vector-derived products, prior knowledge and platform validation, and viral safety in continuous manufacturing. It also shows how Next Generation Sequencing (NGS) can replace or supplement conventional assays when suitably validated, how historical cell-line knowledge can streamline cell-bank testing, how platform data can support low-pH viral inactivation and chromatography-resin reuse strategies, and how continuous processes require careful sampling, traceability, diversion, and virus-clearance planning. This guide converts those training materials into a practical, professional reference while clearly distinguishing official examples from general implementation advice.

Quick answer: The ICH Q5A(R2) training materials explain how the revised viral-safety principles can be applied through case studies on AAV production, prior knowledge/platform validation, and continuous manufacturing. They are illustrative and do not add requirements beyond the guideline.

Why Was the ICH Q5A(R2) Training Programme Created?

The Final Implementation Working Group (IWG) Concept Paper states that the training programme was established to support an aligned interpretation and harmonised implementation of Q5A(R2) across ICH and non-ICH regions. The programme was intentionally designed around the new elements of the revision rather than as a comprehensive course covering every aspect of viral safety.

The Concept Paper identifies the underlying problem clearly: since the original Q5A framework, virus-detection technology, viral-clearance strategies, product platforms, analytical methods, and manufacturing models have evolved. Q5A(R2) therefore introduced new product types, greater flexibility in validation approaches, new assays and analytical methodology, and expectations for continuous manufacturing.

The training materials themselves reinforce an important boundary: they are intended to clarify revised concepts, support implementation through examples, and train industry and regulators. They are not intended to create new regulatory requirements, endorse a specific technology, restrict other justified scientific approaches, or prescribe a single test method.

Critical interpretation rule: Treat the case studies as implementation examples, not mandatory templates. The official slides repeatedly state that other scientifically justified, risk-based approaches may be acceptable.

Structure of the Official Q5A(R2) Training Modules

Module	Main subject	Primary implementation question
Module 0	Introduction and training overview	What changed in Q5A(R2), and how should the training examples be interpreted?
Module 1	New Product Types	How can the three viral-safety principles be applied to AAV products made by plasmid transfection or baculovirus expression?
Module 2	Prior Knowledge and Platform Validation	When can previous cell-line, low-pH, and chromatography-resin experience support reduced product-specific testing?
Module 3	Continuous Manufacturing	How should sampling, viral clearance, unit-operation disturbances, traceability, and material diversion be addressed in a continuous process?

The training programme was anticipated in the IWG Concept Paper through case studies covering new product types, prior knowledge and platform approaches, resin reuse, molecular methods, and continuous manufacturing. The completed May 2025 training reflects that plan through Modules 0–3.

The Three-Pronged Viral-Safety Approach

Module 0 centres the training on the three principal, complementary viral-safety controls in Q5A(R2):

1. Control the sourcesSelect and test cell lines, raw materials, and media components for undesirable infectious viruses.

2. Demonstrate clearanceAssess whether the production process can remove or inactivate adventitious and endogenous viruses.

3. Test during productionTest at appropriate manufacturing stages to demonstrate the absence of contaminating infectious viruses.

This framework is then reused throughout the training examples. The value of the training is not simply the individual test lists; it shows how the same three principles can be adapted to new modalities, platform processes, and continuous operations.

Module 1: New Product Types and AAV Viral Safety

Module 1 applies Q5A(R2) Annex 6 principles to two recombinant AAV production examples:

Example 1: AAV vector produced by triple plasmid transfection in HEK-293 cells.
Example 2: Baculovirus-expressed AAV vector produced in Sf9 insect cells.

The training evaluates raw and starting materials, cell substrate testing, virus seeds where applicable, unprocessed bulk/harvest testing, purified bulk testing, model-virus selection, and viral clearance.

New terminology: Production Virus

The training defines a production virus as a process-related virus that includes a helper virus or a viral vector used for protein expression. A helper virus provides functions needed by a replication-deficient co-infecting virus, while a viral vector for protein expression can be used to express recombinant protein, virus-like particles, or another viral vector.

Feature	HEK-293 plasmid transfection	Sf9 baculovirus expression
Cell substrate	Human HEK-293	Insect Sf9
Production virus	Not used in the same way as the baculovirus platform	Recombinant baculovirus is a production virus
Animal-derived materials during routine manufacture	None in the training example	None in the training example
Historical raw-material risk	Bovine serum and porcine trypsin were used in cell-line history	Non-inactivated bovine serum and porcine trypsin were used in cell-line history
Additional virus risks	Human-cell-line-specific considerations and replication-competent AAV	Retrovirus-like particles, Sf9 rhabdovirus, baculovirus, and replication-competent AAV considerations

Example 1: HEK-293 Triple Plasmid Transfection

In the HEK-293 example, the Master Cell Bank was established in chemically defined medium without human- or animal-derived components, even though bovine serum and porcine trypsin had been used earlier in the cell-line history. The training uses this history to illustrate why raw-material risk assessment should consider both current manufacturing inputs and historical exposures.

Cell-bank testing

The example includes retrovirus/endogenous-virus testing, adventitious-virus testing, and specific-virus testing. A 28-day in vitro assay is shown using MRC-5, Vero, and HEK-293 indicator cells. Non-targeted NGS is presented as a replacement for the in vivo assay, and molecular methods can replace selected species-specific virus tests when appropriately validated.

Unprocessed bulk and purified bulk

The unprocessed bulk/harvest is tested for adventitious viruses using indicator cell systems. In this example, replication-competent AAV testing is performed on the drug substance because the AAV vector concentration is expected to be higher there, supporting improved detection sensitivity.

Viral-clearance model viruses

The training presents Case A for the HEK-293 system and uses non-specific model viruses representing different physicochemical properties. The example includes MLV, BVDV, adenovirus type 2, and murine parvovirus, with affinity chromatography and medium virus filtration evaluated according to relevance. The slides explicitly state that Q5A does not define an overall virus-reduction target for this Case A example.

Example 2: Baculovirus-Expressed AAV in Sf9 Cells

The Sf9 example is more complex because the platform includes a production virus and additional known cell-substrate-associated viral risks. The training therefore demonstrates how Q5A Cases B, C, and F can be combined with both specific and non-specific model viruses.

Cell-substrate and seed testing

In the example, PERT and TEM are positive for retroviral-like particles associated with Sf9 cells, while prior knowledge is used to explain why a human-cell-line infectivity study for those particles is not performed. In vitro adventitious-virus testing uses Sf9, MRC-5, Vero, and BHK-21 cells. Targeted NGS can replace selected specific-virus assays, and non-targeted NGS is used as a replacement for an in vivo test on the baculovirus master virus seed.

Production-virus and rhabdovirus considerations

The training illustrates direct measurement of high baculovirus levels entering purification and quantification of Sf9 rhabdovirus for viral-safety calculations. Specific model viruses are selected because the production system contains known viral risks, while non-specific models add robustness.

Clearance strategy

The baculovirus/Sf9 example includes detergent viral inactivation, affinity capture chromatography, ion-exchange chromatography, and virus filtration. The training shows illustrative log-reduction data for baculovirus, VSV, MLV, reovirus, and parvovirus and calculates estimated residual particles per dose. These values are examples from the training case study and should not be treated as universal targets.

Practical lesson from Module 1: The viral-safety strategy changes with the production platform. A process using a production virus, a cell substrate with endogenous viral particles, or a specific known viral risk generally requires a more targeted clearance and testing strategy than a Case A system.

How the Training Uses Next Generation Sequencing

NGS appears across the training as an enabling technology rather than a mandated platform. The official materials repeatedly state that they do not endorse a specific technology.

NGS use in the training	Illustrative application
Non-targeted NGS replacing in vivo assays	Used in AAV cell-bank examples and baculovirus seed testing.
Non-targeted NGS supplementing or replacing in vitro assays	Can be considered where justified and suitable for intended use.
Targeted NGS replacing species-specific testing	Illustrated for defined virus risks in cell substrates.
Rapid testing in continuous manufacturing	Supports faster decisions on contamination control and diversion.

The training explains that a head-to-head comparison with conventional in vivo or in vitro assays is not necessarily appropriate because the assay endpoints differ and NGS offers broader detection capability. Where NGS is used as a replacement assay, the training examples assume a validation package and matrix-specific verification demonstrating suitability.

Important boundary: The IWG Concept Paper explicitly states that the programme would highlight where NGS could replace conventional testing but would not provide a full technical course on NGS validation.

Module 2: Prior Knowledge and Platform Validation

Module 2 uses a hypothetical CHO-derived monoclonal antibody, mAb X, to show how prior knowledge can streamline three areas:

Master Cell Bank virus testing.
Low-pH virus inactivation.
Viral-clearance studies with used chromatography resin.

Prior knowledge in MCB testing

The CHO parental cell bank in the example had already been used to generate MCBs for multiple products and had a substantial testing history. The new mAb X MCB was generated without animal- or human-derived reagents, and all raw materials were documented.

The training then presents two acceptable testing approaches. One uses conventional assays with selected tests omitted based on prior knowledge; the other uses validated NGS to replace the in vivo assay and additional virus-specific tests. The conclusion is not that one option is universally preferred, but that both can be adequate when the risk assessment considers the CHO cell-line knowledge, parental bank history, and how the new MCB was generated.

Platform Example: Low-pH Virus Inactivation

The low-pH case study shows how internal and external prior knowledge can support omission of a new product-specific viral-inactivation study. Three earlier monoclonal antibodies—mAbs A, B, and C—were manufactured by the same company using a similar platform, and low-pH inactivation data were available from all three.

The training cites the Q5A(R2) platform example stating that treatment at pH ≤ 3.6, temperature ≥ 15°C, time ≥ 30 minutes, and sodium chloride ≤ 500 mmol/L is effective for XMLV under the described platform conditions. In the worked example, mAb X manufacturing conditions are compared with the previous viral-clearance studies to show that the platform data cover or challenge the new product conditions.

Conservative reduction-factor claim

The training recommends a conservative reduction-factor claim when leveraging prior knowledge. In the illustrative dataset, the lowest relevant platform result is used to support the claim for mAb X rather than selecting the highest available value. This demonstrates an important principle: platform knowledge should reduce unnecessary repetition without overstating process capability.

Do not generalise the case-study numbers: The pH, time, temperature, and reduction values shown in the training are tied to the example and cited Q5A platform conditions. A real product still needs a scientifically justified assessment of comparability and applicability.

Platform Example: Used Chromatography Resin

The third Module 2 example considers whether mAb X needs a dedicated viral-clearance study using aged AEX resin. Product-specific clearance had already been established using naïve resin, and the production column was intended for up to 50 cycles.

The example combines external and internal prior knowledge: effective virus inactivation by 0.5 M NaOH sanitisation, literature indicating that AEX resin reuse does not adversely affect viral clearance, in-house used-resin data from other monoclonal antibodies, the same resin brand, similar operating conditions, similar buffer chemistry, comparable process intermediates, and product-specific evidence that purification performance remains effective through the intended cycle life.

Based on that combined evidence, the training concludes that a product-specific viral-clearance study with used AEX resin is not needed in the example. It immediately adds a regulatory reminder: real applications require robust justification and an adequate data package before prior knowledge is used to gain flexibility.

Module 3: Viral Safety in Continuous Manufacturing

Module 3 applies the Q5A(R2) viral-safety framework to a continuous or hybrid monoclonal-antibody process based on the ICH Q13 Annex III example. The process includes a perfusion bioreactor, continuous capture chromatography, virus inactivation, polishing chromatography, virus filtration, and buffer exchange/concentration.

What changes in continuous manufacturing?

The training does not change the basic viral-safety principles. Instead, it highlights new process risks created by extended duration and connected operations:

Longer cell-culture runs.
Need to define sampling periodicity.
Potential propagation of disturbances from one unit operation to another.
More complex material traceability.
Need for predefined diversion strategies.
Multi-column capture operation and cycle-to-cycle carryover considerations.
Residence-time control during continuous virus inactivation.
Extended virus-filter use, filter changes, and post-use integrity testing.

Upstream and batch definition

The training describes one or more perfusion bioreactors integrated with continuous downstream processing. A run may contain multiple sequential harvests, and a batch can represent a defined quantity of protein from several harvests filled into one drug-substance fill. The general cell-line qualification approach, including LIVCA, remains applicable, but LIVCA should be demonstrated for the new continuous process because operating duration may differ substantially from an existing batch process.

Unprocessed bulk testing

The training illustrates a flexible testing strategy in which testing does not need to map one-to-one to every harvest. Rapid methods such as NGS can support faster material-diversion decisions. Testing frequency should balance process understanding, potential material loss, and risk, and the example states that each batch/drug-substance fill should have at least one adventitious-virus test.

Continuous capture chromatography

Multi-column capture can involve staggered loading, overloading/breakthrough strategies, parallel loading, washing, elution, regeneration, and sanitisation. The training highlights potential virus carryover, synchronisation of cleaning and regeneration, process/feed variability, and the relationship between loading conditions and virus-removal performance.

Continuous viral inactivation

Continuous inactivation uses a defined flow path and residence-time distribution instead of a simple batch hold. The same critical concepts remain relevant—pH, temperature, and exposure time—but flow must be translated into effective residence time. The training emphasises establishing and justifying a narrow distribution, monitoring pH throughout the run, understanding the minimum residence time, and diverting material when excursions occur.

Connected polishing chromatography

When polishing steps are directly connected, disturbances in the first step can change the load conditions for the second. The training therefore highlights control of pH, conductivity, impurities, inline adjustment, and the potential for virus carryover between cycles.

Extended virus filtration

The same general principles for virus filtration and integrity testing apply, but a long campaign requires a process design that allows filter changes and post-use integrity testing. The training also discusses alternative virus-spiking strategies, including bracketed approaches, and the need to demonstrate performance over the intended filter life.

Testing, Traceability, and Material Diversion

Diversion is one of the most practical themes in Module 3. The training states that traceability must be maintained if material is to be diverted selectively. Appropriate diversion points should be designed into the process, and no affected material should be released until the investigation is complete.

The example further illustrates that all positive material and subsequent affected harvests should be diverted and discarded, while other material may potentially be considered depending on traceability, testing history, sampling strategy, and the timing of the event.

Continuous-manufacturing lesson: A continuous process is not made safe by simply increasing test frequency. The control strategy should combine process understanding, appropriate sampling, rapid detection where useful, traceability, integrity testing, and an executable diversion plan.

Applying the Training in a Pharmaceutical Quality System

Implementation should remain within the site's cGMP framework and controlled SOP system. Viral-safety strategies may affect analytical procedures, manufacturing controls, sampling plans, validation protocols, equipment and computerized systems, deviation management, and regulatory submissions.

Where equipment qualification is relevant, lifecycle documentation can include URS, DQ, IQ, OQ, and PQ, as appropriate.

NGS data, virus-clearance calculations, model-virus selection, test results, diversion decisions, and prior-knowledge assessments should remain traceable and reviewable in accordance with ALCOA+ principles. Significant contamination events or systemic control failures should be investigated and, where appropriate, managed through CAPA.

ICH Q5A(R2) Training Implementation Checklist

Identify which training module applies. New modality, prior knowledge/platform validation, or continuous manufacturing may require different implementation logic.
Separate examples from requirements. Do not copy case-study test panels or clearance targets without product-specific justification.
Apply the three-pronged viral-safety framework. Review source control, process clearance, and testing at appropriate stages.
Map product- and platform-specific viral risks. Include cell-line history, raw materials, endogenous viruses, production viruses, and replication-competent virus risks where relevant.
Justify molecular-method use. Where NGS replaces or supplements conventional assays, establish suitability, validation/qualification, and matrix verification appropriate to intended use.
Document prior knowledge. Demonstrate why historical cell-line, low-pH, chromatography, or platform information is applicable to the new product.
Use conservative platform claims. Avoid overstating viral-clearance capability when deriving claims from prior knowledge.
For continuous manufacturing, design traceability and diversion together. Sampling, testing frequency, integrity testing, and diversion logic should be mutually compatible.
Assess regulatory impact. Ensure the justification is reflected appropriately in development reports, validation packages, and marketing applications.
Maintain complete evidence. Preserve source data, risk assessments, calculations, model assumptions, raw results, and approvals under the pharmaceutical quality system.

Key Takeaways

The Q5A(R2) IWG training programme was created to support aligned interpretation and harmonised implementation, especially for new elements introduced by the revision.
The official May 2025 materials contain Modules 0–3: Introduction, New Product Types, Prior Knowledge/Platform Validation, and Continuous Manufacturing.
The examples are illustrative and do not add requirements or prescribe one technology.
Module 1 uses HEK-293 plasmid-transfection and Sf9/baculovirus AAV platforms to demonstrate different viral-risk and clearance strategies.
NGS is shown as a replacement or supplemental method in multiple case studies when suitability is adequately demonstrated.
Module 2 shows how prior cell-line history and platform data can streamline MCB testing, low-pH viral inactivation, and used-resin clearance studies.
The low-pH platform example demonstrates how conservative claims can be derived from relevant prior data rather than repeating every product-specific study.
Module 3 focuses on extended culture, sampling periodicity, connected operations, residence-time control, virus filtration, traceability, and diversion.
Continuous manufacturing still follows the same three-pronged viral-safety principles used for conventional manufacturing.
The core regulatory skill is not copying the example—it is constructing a scientifically justified data package showing why the chosen strategy is appropriate for the specific product and process.

Conclusion

ICH Q5A(R2) training translates the revised viral-safety guideline into practical implementation scenarios. Its strongest value is the way it demonstrates scientific reasoning: new product types require platform-specific risk assessment; modern molecular methods can replace older tests when properly justified; prior knowledge can reduce repetitive validation when comparability is convincing; and continuous manufacturing requires integrated control of sampling, traceability, process disturbances, and diversion.

The training should therefore be used as an implementation aid rather than a checklist of mandatory methods. Pharmaceutical and biotechnology companies should preserve the underlying Q5A(R2) principles, develop product-specific risk assessments, document the relevance of prior knowledge, and place all testing and clearance strategies within a robust cGMP quality system. When used this way, the training can support more efficient, globally aligned viral-safety submissions without weakening scientific control.

Frequently Asked Questions About ICH Q5A(R2) Training

1. What is the purpose of the ICH Q5A(R2) training material?

It was developed to clarify revised viral-safety concepts and support aligned implementation through practical case studies for regulators and industry. It is not a replacement for the guideline.

2. What are the main Q5A(R2) training modules?

The May 2025 training contains Module 0 Introduction, Module 1 New Product Types, Module 2 Prior Knowledge and Platform Validation, and Module 3 Continuous Manufacturing.

3. Does the training create new regulatory requirements?

No. The training explicitly states that it does not introduce additional requirements, prescribe specific tests, or endorse a specific technology.

4. Which new-product examples are used in Module 1?

Module 1 uses an AAV vector produced by triple plasmid transfection in HEK-293 cells and an AAV vector produced using recombinant baculovirus in Sf9 insect cells.

5. How is NGS used in the training?

NGS is shown as a replacement or supplemental method for selected conventional assays, including in vivo testing and some species-specific virus tests, when the method is validated or otherwise demonstrated suitable for intended use.

6. What is the main example in Module 2?

Module 2 uses a hypothetical CHO-derived monoclonal antibody, mAb X, to demonstrate prior knowledge in MCB testing, low-pH virus inactivation, and used chromatography resin.

7. Can prior knowledge eliminate product-specific viral-clearance studies?

It can in some circumstances when the prior data are relevant, the platform is sufficiently similar, critical parameters and intermediates are comparable, and the justification is supported by an adequate data package.

8. What continuous-manufacturing risks are highlighted in Module 3?

Key risks include extended culture duration, sampling periodicity, connected-unit-operation disturbances, residence-time control, filter life, traceability, and diversion of potentially affected material.

9. Does every continuous-manufacturing harvest need a separate adventitious-virus test?

No. The training example states that testing does not need to map individually to each harvest. The overall testing frequency should be justified from process understanding, and the example includes at least one adventitious-virus test for each batch/drug-substance fill.

10. What is the most important implementation lesson from the training?

The case studies should be used to understand regulatory reasoning, not copied as mandatory templates. Each product and process requires a scientifically justified viral-safety strategy supported by suitable data.

Editorial source note: This article is an original explanatory adaptation of the ICH Q5A(R2) Final IWG Concept Paper endorsed in December 2023 and the official Q5A(R2) Training Material Modules 0–3 published in May 2025. The official training states that its examples are illustrative, do not create additional requirements, and do not endorse a specific technology. Added quality-system discussion is provided for practical context and does not replace the Q5A(R2) guideline, regional regulatory requirements, or an approved product dossier.